Menu Search
Equities

Agios Pharmaceuticals Inc

8AP:MUN

Agios Pharmaceuticals Inc

Actions
  • Price (EUR)23.80
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+31.49%
  • Beta--
Data delayed at least 15 minutes, as of Jun 02 2023 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (LR MDS), and hemolytic anemias.

  • Revenue in USD (TTM)19.02m
  • Net income in USD-218.05m
  • Incorporated2007
  • Employees389.00
  • Location
    Agios Pharmaceuticals Inc88 Sidney StreetCAMBRIDGE 02139United StatesUSA
  • Phone+1 (617) 649-8600
  • Fax+1 (302) 655-5049
  • Websitehttps://www.agios.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.